Position statements and other documents from the National Bowel Cancer Working Group.
Flexible Sigmoidoscopy as a Screening Test in the National Bowel Screening Programme
This statement sets out the Ministry's position on flexible sigmoidoscopy as a bowel screening method. The statement supports the current use of Faecal Immunochemical Testing (FIT) in the National Bowel Screening Programme rather than flexible sigmoidoscopy.
Molecular Testing of Colorectal Cancers in New Zealand: Minimum standards for molecular testing of newly diagnosed colorectal cancers
The molecular testing standard sets out the expected level of testing for patients who have received a new diagnosis of colorectal cancer. The standards relate to Mismatch Repair, BRAF and RAS Mutation testing.
National Bowel Cancer Working Group Māori Equity Statement 2017
The National Bowel Cancer Working Group have developed a Māori equity statement 2017. The statement provides a high level summary of inequities that exist between Māori and non-Māori in bowel cancer survival, and highlights actions that clinicians and health providers can take to help address this issue.
These criteria are designed to cover the majority of indications for referral for colonoscopy by general practitioners and non-gastrointestinal specialists.
The 2019 updates include the addition of a chapter around how to manage people who do not meet the referral criteria.
National Bowel Cancer Working Group position statement on the use of CT colonography and barium enema
The National Bowel Cancer Working Group (NBCWG) has reviewed the available evidence (both national and international) and decided that CT colonography (CTC) is a superior colonic imaging technique than barium enema for detecting colorectal cancer.